Polidocanol: A Review of Off-Label Dermatologic Uses

被引:3
|
作者
Nguyen, Quoc-Bao D. [1 ,2 ]
Stender, Carly [3 ]
Bur, Delfina [3 ]
Silapunt, Sirunya [1 ]
机构
[1] Univ Texas Houston, Dept Dermatol, McGovern Med Sch Houston, 6655 Travis St,Suite 980, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
[3] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
关键词
SODIUM TETRADECYL SULFATE; PROSPECTIVE COMPARATIVE TRIAL; TELANGIECTATIC LEG VEINS; DIGITAL MUCOUS CYSTS; SOFT-TISSUE TUMORS; FOAM SCLEROTHERAPY; DOUBLE-BLIND; DETERGENT SCLEROSANTS; PERIOCULAR VEINS; VARICOSE;
D O I
10.1097/DSS.0000000000003520
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND Polidocanol is an FDA-approved treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, but numerous other off-label dermatological applications have been reported. OBJECTIVE To describe the various off-label dermatological clinical uses of polidocanol, as well as efficacy and adverse effects. METHODS The review of studies searchable on PubMed from 2004 to 2021 describing clinical uses of polidocanol to determine efficacy and adverse effects associated with various dermatologic applications. RESULTS Polidocanol has shown efficacy in the treatment of mucocele of minor salivary gland, hemangioma, upper extremity veins, reticular veins of the chest, facial veins, pyogenic granuloma, lymphangioma circumscriptum, digital mucous cyst, mixed skin ulcers, cutaneous focal mucinosis, seromas, glomuvenous malformations, acne cysts, lymphocele, and dissecting cellulitis. Commonly reported side effects include pain, erythema, swelling, ecchymosis, and ulceration. Most sources were case reports and small prospective studies, as such the strength of data supporting many uses is limited by small sample sizes and lack of controls. CONCLUSION Although polidocanol is currently only FDA approved for incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, the use of polidocanol has been selected for a variety of off-label clinical applications.
引用
收藏
页码:961 / 966
页数:6
相关论文
共 50 条
  • [41] OFF-LABEL USES OF LOW-DOSE RITUXIMAB: A SYSTEMATIC REVIEW OF THE LITERATURE
    Fernandez-Martinez, M.
    Esterlich, E.
    Vallano, A.
    Danes, I.
    Agusti, A.
    [J]. CLINICAL THERAPEUTICS, 2015, 37 (08) : E117 - E118
  • [42] Off-Label Uses of Medication and Therapies in Wound Care
    Treadwell, Terry
    [J]. WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE, 2010, 22 (04): : 87 - 87
  • [43] Justification of off-label antibiotics uses in hospitalized children
    Berthod, Christelle
    Kassai, Behrouz
    Boussageon, Remy
    Adelaide, Leopold
    Jacquet-Lagreze, Matthias
    Lajoinie, Audrey
    [J]. THERAPIE, 2017, 72 (06): : 649 - 658
  • [44] Off-Label Uses of Deoxycholic Acid in Body Contouring
    Zarbafian, Misha
    Fabi, Sabrina G.
    [J]. DERMATOLOGIC SURGERY, 2020, 46 : S2 - S7
  • [45] Efficacy of Quetiapine Off-Label Uses Data Synthesis
    Carney, Adam C.
    [J]. JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2013, 51 (08) : 11 - 18
  • [46] Sacubitril/Valsartan Off-Label Uses for Heart Failure
    Kido, Kazuhiko
    Colvin, Bailey M.
    Szymanski, Thomas W.
    Guglin, Maya
    [J]. JOURNAL OF CARDIAC FAILURE, 2022, 28 (07) : 1185 - 1201
  • [48] Off-label uses of new biologic agents in dermatology
    Sanchez-Cano, Daniel
    Callejas-Rubio, Jose L.
    Antonia Fernandez-Pugnaire, M.
    Teresa Gutierrez-Salmeron, M.
    Ortego-Centeno, Norberto
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB48 - AB48
  • [49] Off-label uses of denosumab in metabolic bone diseases
    Polyzos, Stergios A.
    Makras, Polyzois
    Tournis, Symeon
    Anastasilakis, Athanasios D.
    [J]. BONE, 2019, 129
  • [50] Products liability and ''off-label'' uses of prescription drugs
    Stoffelmayr, KJ
    [J]. UNIVERSITY OF CHICAGO LAW REVIEW, 1996, 63 (01): : 275 - 306